Oppenheimer Asset Management Inc. cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 70.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 59,051 shares of the company's stock after selling 138,148 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Takeda Pharmaceutical were worth $782,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of TAK. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical in the fourth quarter valued at $26,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $40,000. BNP Paribas Financial Markets boosted its holdings in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares in the last quarter. Smithfield Trust Co boosted its holdings in shares of Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Takeda Pharmaceutical in the third quarter valued at about $52,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.
Takeda Pharmaceutical Stock Performance
Shares of NYSE:TAK traded up $0.18 during midday trading on Friday, hitting $15.18. The stock had a trading volume of 1,575,024 shares, compared to its average volume of 1,816,164. The company has a market capitalization of $48.29 billion, a PE ratio of 37.94, a P/E/G ratio of 0.24 and a beta of 0.46. The stock has a 50 day moving average price of $13.59 and a two-hundred day moving average price of $13.91. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.22.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
